Moderna makes progress with combined COVID-19 and seasonal flu vaccine

this combined vaccine modern For COVID-19 and seasonal influenza ha Shows promising resultsbased on results from a Phase 1/2 trial.

The vaccine has shown Stronger immune response than standard dose flu vaccine in adults 50 to 64 years oldas A modified influenza vaccine for people ages 65 to 79.

He also received Strong immune response to COVID-19, safe and has similar side effects Previous immunizations.

“With today’s positive results for our combined influenza and COVID-19 vaccine, we continue to expand our products in Phase 3 development,” the company said Moderna CEO or General Manager Stéphane Bancelin a company press release.

“this Flu and COVID-19 represent Significant seasonal burden on individuals, providers, health systems and the economy

.this combined vaccine provides an important opportunity Improve consumer and provider experience, increase compliance with public health recommendations, and create value for health systems” added Bancel.

Moderna points out Impact of influenza on health systems with 3 to 5 million seriously ill patientsand The number of people who have died from the disease ranges from 290,000 to 650,000.

about Coronavirus diseasethey have already registered Approximately 770 million COVID-19 cases and 7 million deaths worldwide. Those most affected are older adults and people with pre-existing conditions.

“They are managed Approximately 150 million doses of influenza vaccine are administered each year in the United States

and expected COVID-19 vaccines for this fall Between 500 million and 100 million doses have been produced this year” Modena said.

modern waiting Receive federal regulatory approval for combined vaccine in 2025so people will need to receive a separate vaccine before then.

Continue reading story

“We are pleased to advance the combined respiratory vaccine into Phase 3 development and look forward to working with public health officials to address the significant seasonal threat these viruses pose to humans,” Bancel noted.

What do analysts say?

according to prompt levelModerna has Comments from 13 analysts are divided into 6 buys, 6 holds, and 1 sell. The average target price is $163.36, with the highest forecast being $285 and the lowest forecast being $97.. The average price target represents a 56.43% change from Tuesday’s closing price.

modern Tuesday’s closing price was $104.24. The 70-period moving average is above the latest candle, the RSI rose to 49 points, and the MACD line remains below zero.